Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
24.03
+1.99 (9.03%)
At close: Oct 23, 2026, 4:00 PM EDT
24.50
+0.47 (1.96%)
After-hours: Oct 23, 2026, 4:56 PM EDT
Zai Lab Revenue
Zai Lab had revenue of $106.31M in the quarter ending June 30, 2026, a decrease of -3.33%. This brings the company's total for the last twelve months to $449.61M, up 5.10% year-over-year. In the year 2025, Zai Lab had annual revenue of $460.16M with 15.33% growth.
Revenue (ttm)
$449.61M
Revenue Growth
+5.10%
P/S Ratio
6.00
Revenue / Employee
$252,026
Employees
1,784
Market Cap
2.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 460.16M | 61.17M | 15.33% |
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| ADMA Biologics | 512.28M |
| Aurinia Pharmaceuticals | 311.51M |
| Beam Therapeutics | 156.04M |
| Arcus Biosciences | 117.00M |
| Precigen | 85.72M |
| Viridian Therapeutics | 71.13M |
| NewAmsterdam Pharma Company | 7.12M |
ZLAB News
- 7 hours ago - Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study - MarketBeat
- 9 hours ago - Zai Lab Transcript: Investor update - Transcripts
- 9 hours ago - Zai Lab Press release: Investor update - Filings
- 9 hours ago - Zai Lab Slides: Investor update - Filings
- 10 hours ago - Zai Lab reports results from Phase 1b trial of zocilurtatug pelitecan - TheFly
- 10 hours ago - Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer - Business Wire
- 20 hours ago - Zai Lab announces $250M private placement - TheFly
- 20 hours ago - Zai Lab Announces $250 Million Private Placement - Business Wire